The Patent Finder
LI

Lxo Ireland Designated Activity Company

First filing 2012
OverviewNotableFeesChangesFamiliesPatent listSources & methods

27 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6 more records may belong here and await a decision; they are not counted.

The next term ends in Mar 2031. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2031
Next term end
4
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 18, 2026
    The maintenance fee for Combinations of Amisulpride and Another Anti-Emetic for Treating Nausea and Vomiting (US 10,322,106) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
  • 1 fee due Jan 21, 2027
    The maintenance fee for Use of Amisulpride as an Anti-Emetic (US 9,084,765) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
  • 1 fee due Feb 28, 2027
    The maintenance fee for Pharmaceutical Compositions and Methods of Using the Same (US 11,738,015) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
  • 3 fees due Mar 1 to 24, 2027 · next Mar 1
  • 1 fee due Jul 7, 2027
    The maintenance fee for Use of Amisulpride as an Anti-Emetic (US 10,525,033) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
  • 1 fee due Aug 27, 2027
    The maintenance fee for Pharmaceutical Compositions and Methods of Using the Same (US 11,911,502) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 8,686,019Use of Amisulpride as an Anti-Emetic
held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc.
In force
 · High confidence
In forceHigh confidence
US 9,119,836Use of Amisulpride as an Anti-Emetic
held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc.
In force
 · High confidence
In forceHigh confidence
US 9,545,426Use of Amisulpride as an Anti-Emetic
held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc.
In force
 · High confidence
In forceHigh confidence
US 9,889,118Use of Amisulpride as an Anti-Emetic
held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc.
In force
 · High confidence
In forceHigh confidence
US 10,085,970Use of Amisulpride as an Anti-Emetic
held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc.
In force
 · High confidence
In forceHigh confidence
US 10,525,033Use of Amisulpride as an Anti-Emetic
held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc.
In force
 · High confidence
In forceHigh confidence
US 12,194,022Use of Amisulpride as an Anti-Emetic
held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc.
In force
 · High confidence
In forceHigh confidence
US 9,084,765Use of Amisulpride as an Anti-Emetic
held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc.
In force
 · High confidence
In forceHigh confidence
US 10,322,106Combinations of Amisulpride and Another Anti-Emetic for Treating Nausea and Vomiting
held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc.
In force
 · High confidence
In forceHigh confidence
US 9,867,815Pharmaceutical Compositions and Methods of Using the Same
In force
 · High confidence
In forceHigh confidence
10 of 27 patents shown.
Pro members see all 27.
Pro members: see all 27 patents
Also on record, not counted in the 27: 3 applications pending · 5 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited